Welcome to our dedicated page for Pyxis Oncology SEC filings (Ticker: PYXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pyxis Oncology, Inc. filings document a clinical-stage oncology company developing MICVO, an investigational antibody-drug conjugate for difficult-to-treat cancers. Its 8-K reports cover financial results, corporate updates, Regulation FD presentations, clinical data disclosures, and trial-related updates for MICVO in recurrent or metastatic head and neck squamous cell carcinoma and other advanced solid tumors.
The company’s regulatory record also includes proxy materials for annual meeting matters, director elections, governance proposals, executive transitions, employment and separation arrangements, equity compensation matters, and emerging growth company status. These filings describe Pyxis Oncology’s public-company governance, program disclosures, capital-related arrangements, and risk-linked clinical development reporting.
Pyxis Oncology, Inc. (PYXS) reported updated Phase 1 monotherapy data for its lead antibody-drug conjugate micvotabart pelidotin (MICVO) in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma as of August 18, 2026. At the 5.4 mg/kg dose with a cap, the efficacy-evaluable cohort of 33 patients showed a 36% confirmed objective response rate and 94% disease control rate, with 75% of responders improving by the first six-week scan and 83% achieving more than 50% tumor reduction.
Median progression-free survival was 6.2 months and 12‑month overall survival probability was 79%, while median overall survival had not yet been reached. In the 35‑patient safety population, 91.4% experienced treatment-related adverse events and 54.3% had grade ≥3 events, including peripheral neuropathy and ocular events, but no treatment-related deaths were reported. The company plans an End of Phase 2 meeting in early 2027 and initiation of a pivotal ~500‑patient Phase 3 "Headliner" trial in mid‑2027, and MICVO holds FDA Fast Track Designation in this setting.
Pyxis Oncology, Inc. (PYXS) reported that CEO and Chairman Thomas Civik received a grant of stock options covering 2,503,050 shares of common stock on September 4, 2026. The options have an exercise price of $3.89 per share and expire on September 4, 2036. The award vests over four years, with 25% vesting on the first anniversary of September 4, 2026 and the remainder vesting in 36 equal monthly installments, subject to his continued employment. No Rule 10b5-1 trading plan is reported for this award.
Pyxis Oncology, Inc. (PYXS) appointed Thomas Civik, previously Interim Chief Executive Officer, as permanent Chief Executive Officer effective September 4, 2026, and also named him Chairman of the Board. John Flavin, co-founder and former Chairman, became Lead Independent Director and Chair of the Compensation Committee, preserving independent board oversight.
Under an amended employment agreement, Civik receives a $710,000 annual base salary, a target bonus equal to 60% of salary, a $100,000 one-time sign-on bonus subject to clawback within six months, and a stock option for 2,503,050 shares vesting over four years with accelerated vesting protections upon certain terminations around a Change in Control. Standard severance includes up to 12 months of salary and COBRA, increasing to 18 months of salary plus target bonus and COBRA in specified Change in Control scenarios.
The company also reported that director Santhosh Palani resigned for professional time-commitment reasons, the board size was reduced from eight to seven, and his unvested equity awards were fully accelerated with option exercise periods extended. Pyxis highlighted upcoming 2026 clinical data updates for its lead ADC candidate MICVO in recurrent/metastatic head and neck cancer.
Pyxis Oncology, Inc. (PYXS) filed a resale prospectus covering up to 39,200,306 shares of common stock to be sold from time to time by existing investors. This includes 19,600,153 Initial Shares issued in a July 2, 2026 private placement and 19,600,153 Common Warrant Shares issuable upon exercise of accompanying warrants.
Pyxis will not receive proceeds from sales by the selling stockholders, but could receive up to $64.0 million in gross proceeds if all warrants are exercised for cash; the warrants are exercisable at $3.289 per share and may be exercised cashlessly, in which case Pyxis receives no proceeds. Common stock outstanding was 83,408,050 shares as of August 19, 2026, and the stock last traded at $3.37.
The July 2026 private placement raised approximately $50 million at $2.551 per share. Pyxis plans to use any cash warrant-exercise proceeds to advance its lead ADC candidate MICVO in recurrent/metastatic head and neck squamous cell carcinoma and for working capital and general corporate purposes. The company is an emerging growth company and smaller reporting company, and its most recent audited financials include an auditor’s explanatory paragraph about substantial doubt regarding its ability to continue as a going concern.
Pyxis Oncology, Inc. (PYXS) reported that director Jakob Dupont received a grant of 46,000 stock options on August 20, 2026. The options have an exercise price of $3.12 per share, expire on August 20, 2036, and will vest in equal monthly installments through October 31, 2026, subject to his continued service. Following this award, he holds 46,000 options directly.
Pyxis Oncology, Inc. (PYXS) has filed a resale shelf registration covering up to 39,200,306 shares of common stock for selling stockholders. This consists of 19,600,153 Initial Shares issued in a July 2, 2026 private placement and 19,600,153 Common Warrant Shares issuable upon exercise of accompanying warrants.
The company will not receive proceeds from stockholder resales, but could receive up to $64.0 million in gross proceeds if the Common Warrants are exercised in full for cash; the warrants are exercisable at $3.289 per share and may also be exercised on a cashless basis. The private placement itself raised approximately $50 million in gross proceeds at $2.551 per share. Shares outstanding were 83,408,050 as of August 19, 2026.
Pyxis is a clinical-stage oncology company focused on solid tumors, with lead ADC candidate MICVO in Phase 1 studies for recurrent and metastatic head and neck squamous cell carcinoma, both as monotherapy and in combination with KEYTRUDA. Pyxis qualifies as an emerging growth company and a smaller reporting company. The most recent audited financial statements, incorporated by reference, include an auditor’s explanatory paragraph about substantial doubt regarding the company’s ability to continue as a going concern.
Pyxis Oncology, Inc. reported that Interim CEO and director Thomas Civik acquired a performance-based stock option covering 250,956 shares of common stock. The option, with an exercise price of $1.49 per share and expiration on February 3, 2036, became vested in full on August 12, 2026 after the Board determined that performance conditions tied to a successful financing or strategic transaction had been met. Following this grant, Civik directly holds options for 941,087 shares.
Pyxis Oncology, Inc. reported a net loss of $25.3 million for the quarter and $48.6 million for the six months ended June 30 2026, with an accumulated deficit of $491.8 million. Cash, cash equivalents and marketable debt securities totaled $33.0 million at quarter end, and management stated there is substantial doubt about the company’s ability to continue as a going concern over the next year without additional financing.
Subsequent to quarter end, Pyxis closed a private placement raising gross proceeds of approximately $50 million and issued common warrants that could provide up to about $64 million more if exercised for cash, which together are expected to fund operations into the second quarter of 2027. The company remains a clinical‑stage oncology business focused on its lead antibody‑drug conjugate MICVO for recurrent and metastatic head and neck squamous cell carcinoma, with ongoing Phase 1 monotherapy and combination studies showing encouraging objective response and disease control rates in heavily pre‑treated patients.
Pyxis Oncology, Inc. reported second quarter 2026 results and detailed progress for its lead antibody-drug conjugate, micvotabart pelidotin (MICVO), in recurrent/metastatic head and neck squamous cell carcinoma. For the quarter ended June 30, 2026, the company recorded a net loss of $25.3 million, or ($0.40) per share, compared with a net loss of $18.4 million, or ($0.30) per share, a year earlier, driven mainly by higher general and administrative expenses.
Research and development expenses were $16.1 million versus $17.1 million in the prior-year quarter, while general and administrative expenses increased to $9.9 million from $5.4 million, largely due to severance and stock-based compensation. As of June 30, 2026, cash, cash equivalents, restricted cash and short-term investments totaled $34.5 million.
The company completed a private placement of up to $114 million, providing approximately $50 million in upfront gross proceeds (of which $10.0 million was received by June 30, 2026) and extending its cash runway into the second quarter of 2027. Updated MICVO monotherapy data in 2L+ R/M HNSCC are expected in Fall 2026, with updated first-line combination data with KEYTRUDA in the fourth quarter of 2026. MICVO holds U.S. FDA Fast Track Designation in R/M HNSCC.